| Novel HER2–targeted therapies for HER2–positive metastatic breast cancer S Kunte, J Abraham, AJ Montero Cancer 126 (19), 4278-4288, 2020 | 154 | 2020 |
| Early-onset pancreas cancer: clinical descriptors, genomics, and outcomes AM Varghese, I Singh, R Singh, S Kunte, JF Chou, M Capanu, W Wong, ... JNCI: Journal of the National Cancer Institute 113 (9), 1194-1202, 2021 | 47 | 2021 |
| Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study S Kunte, L Rybicki, A Viswabandya, R Tamari, A Bashey, A Keyzner, ... Leukemia 36 (3), 856-864, 2022 | 35* | 2022 |
| Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score V Mariotti, DB Page, O Davydov, D Hans, CA Hudis, S Patil, S Kunte, ... Journal of bone oncology 7, 32-37, 2017 | 31 | 2017 |
| Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling RS Smith, I Odintsov, Z Liu, AJW Lui, T Hayashi, M Vojnic, Y Suehara, ... Disease Models & Mechanisms 15 (1), dmm047621, 2022 | 17* | 2022 |
| RET inhibition in novel patient-derived models of RET fusion-positive lung adenocarcinoma reveals a role for MYC upregulation T Hayashi, I Odintsov, RS Smith, K Ishizawa, AJW Liu, L Delasos, ... Disease Models & Mechanisms 14 (2), dmm047779, 2021 | 12 | 2021 |
| Abstract P233: TAS0953/HM06 is effective in preclinical models of diverse tumor types driven by RET alterations I Odintsov, RI Kurth, K Ishizawa, L Delasos, AJW Lui, I Khodos, CJ Hagen, ... Molecular Cancer Therapeutics 20 (12_Supplement), P233-P233, 2021 | 11 | 2021 |
| A case of HLA-DRB1-MET rearranged lung adenocarcinoma with rapid response to crizotinib S Kunte, J Stevenson Clinical Lung Cancer 22 (3), e298-e300, 2021 | 8 | 2021 |
| Combination MET-and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers? FC Santini, S Kunte, A Drilon Translational lung cancer research 6 (3), 393, 2017 | 6 | 2017 |
| Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations I Miyazaki, I Odintsov, K Ishida, AJW Lui, M Kato, T Suzuki, T Zhang, ... Nature Cancer 4 (9), 1345-1361, 2023 | 5 | 2023 |
| Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer M Khorrami, VS Viswanathan, P Reddy, N Braman, S Kunte, A Gupta, ... NPJ Breast Cancer 9 (1), 67, 2023 | 3 | 2023 |
| Poorly differentiated thyroid carcinoma: Single institution series of outcomes S Kunte, J Sharett, W Wei, C Nasr, B Prendes, E Lamarre, J Ku, ... Anticancer Research 42 (5), 2531-2539, 2022 | 3 | 2022 |
| Resazurin microtitre assay (REMA) plate-A simple, rapid and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis S Kunte, A Karmarkar, S Dharmashale, S Hatolkar European Respiratory Journal 40 (Suppl 56), 2012 | 3 | 2012 |
| Radiomics risk score (RRS) on CT to predict survival and response to CDK 4/6 inhibitors in hormone receptor (HR) positive metastatic breast cancer (MBC). S Kunte, N Braman, K Bera, P Leo, J Abraham, AJ Montero, ... Journal of Clinical Oncology 38 (15_suppl), e13041-e13041, 2020 | 2 | 2020 |
| Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations I Miyazaki, I Odintsov, K Ishida, AJW Lui, M Kato, T Suzuki, T Zhang, ... Nature Cancer 4 (10), 1526, 2023 | 1 | 2023 |
| MA13. 05 TA0953/HM06, a Novel RET-specific Inhibitor Effective in Extracranial and CNS Disease Models of NSCLC with RETfusions I Odintsov, AJW Lui, L Delasos, I Khodos, Q Chang, MS Mattar, M Vojnic, ... Journal of Thoracic Oncology 17 (9), S90-S91, 2022 | 1 | 2022 |
| Abstract P5-13-27: Post-treatment vascularity and vessel shape are associated with survival and response to CDK4/6 inhibitors in hormone receptor-positive metastatic breast … VS Viswanathan, N Braman, P Reddy, S Kunte, J Abraham, AJ Montero, ... Cancer Research 82 (4_Supplement), P5-13-27-P5-13-27, 2022 | 1 | 2022 |
| Abstract PS5-42: Change in intra-lesion heterogeneity on CT predicts long-term survival following treatment with CDK4/6 inhibitors in hormone receptor-positive metastatic … N Braman, S Kunte, K Bera, J Abraham, A Montero, A Madabhushi Cancer Research 81 (4_Supplement), PS5-42-PS5-42, 2021 | 1 | 2021 |
| Radiomic heterogeneity as prognostic predictor for treatment with cdk 4/6 inhibitors in hormone receptor-positive metastatic breast cancer A Madabhushi, N Braman, S Kunte, A Montero US Patent App. 17/533,458, 2022 | | 2022 |
| Changes in CT radiomic features predict survival and early response to CDK 4/6 inhibitors in hormone receptor positive metastatic breast cancer A Madabhushi, M Khorrami, V Viswanathan, P Reddy, N Braman, S Kunte, ... | | 2022 |
